Arcus Biosciences (NYSE:RCUS) President Juan Jaen Sells 48,502 Shares

Arcus Biosciences, Inc. (NYSE:RCUS) President Juan Jaen sold 48,502 shares of the stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $30.05, for a total transaction of $1,457,485.10. Following the sale, the president directly owned 842,307 shares of the company’s stock, valued at $25,311,325.35. The trade was a 5.44% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Arcus Biosciences Trading Down 2.7%

Shares of RCUS stock traded down $0.80 during mid-day trading on Monday, reaching $28.12. The stock had a trading volume of 934,888 shares, compared to its average volume of 1,264,033. The firm has a market capitalization of $3.54 billion, a PE ratio of -8.84 and a beta of 0.80. The stock’s 50-day moving average price is $25.93 and its two-hundred day moving average price is $23.49. The company has a current ratio of 4.04, a quick ratio of 4.04 and a debt-to-equity ratio of 0.19. Arcus Biosciences, Inc. has a 52-week low of $8.84 and a 52-week high of $31.74.

Arcus Biosciences (NYSE:RCUS) last posted its earnings results on Tuesday, May 5th. The company reported ($1.02) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.10). The firm had revenue of $17.00 million for the quarter, compared to analysts’ expectations of $29.48 million. Arcus Biosciences had a negative return on equity of 68.97% and a negative net margin of 156.36%.The business’s revenue for the quarter was down 39.3% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.14) earnings per share. Equities analysts expect that Arcus Biosciences, Inc. will post -3.66 earnings per share for the current fiscal year.

Analyst Ratings Changes

RCUS has been the subject of several research analyst reports. Leerink Partners set a $47.00 price objective on Arcus Biosciences in a report on Monday, April 20th. Lifesci Capital assumed coverage on shares of Arcus Biosciences in a report on Thursday, June 4th. They issued an “outperform” rating and a $46.00 price objective for the company. Truist Financial assumed coverage on shares of Arcus Biosciences in a report on Monday, May 18th. They set a “buy” rating and a $35.00 target price on the stock. The Goldman Sachs Group raised their target price on shares of Arcus Biosciences from $30.00 to $34.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Finally, Wedbush lifted their target price on shares of Arcus Biosciences from $37.00 to $41.00 and gave the company an “outperform” rating in a report on Thursday, April 2nd. Eight research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $35.10.

Hedge Funds Weigh In On Arcus Biosciences

Several large investors have recently modified their holdings of RCUS. GAMMA Investing LLC boosted its stake in Arcus Biosciences by 10.0% in the 2nd quarter. GAMMA Investing LLC now owns 3,966 shares of the company’s stock worth $122,000 after purchasing an additional 359 shares in the last quarter. Royal Bank of Canada increased its stake in Arcus Biosciences by 14.6% during the 1st quarter. Royal Bank of Canada now owns 4,758 shares of the company’s stock valued at $102,000 after purchasing an additional 607 shares in the last quarter. Creative Planning increased its stake in Arcus Biosciences by 2.7% during the 3rd quarter. Creative Planning now owns 29,629 shares of the company’s stock valued at $403,000 after purchasing an additional 771 shares in the last quarter. Hantz Financial Services Inc. raised its holdings in Arcus Biosciences by 121.9% in the fourth quarter. Hantz Financial Services Inc. now owns 1,604 shares of the company’s stock worth $38,000 after buying an additional 881 shares during the last quarter. Finally, New York State Teachers Retirement System raised its holdings in Arcus Biosciences by 1.1% in the fourth quarter. New York State Teachers Retirement System now owns 92,431 shares of the company’s stock worth $2,203,000 after buying an additional 1,000 shares during the last quarter. Hedge funds and other institutional investors own 92.89% of the company’s stock.

Arcus Biosciences Company Profile

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.